Chimeric antigen receptor T (CAR-T) cells are effective serial killers with a faster off-rate from dying tumor cells than CAR-T cells binding target cells through their T cell receptor (TCR). Here we explored the functional consequences of CAR-mediated signaling using a dual-specific CAR-T cell, where the same cell was triggered via TCR (tcrCTL) or CAR (carCTL). The carCTL immune synapse lacked distinct LFA-1 adhesion rings and was less reliant on LFA to form stable conjugates with target cells. carCTL receptors associated with the synapse were found to be disrupted and formed a convoluted multifocal pattern of Lck microclusters. Both proximal and distal receptor signaling pathways were induced more rapidly and subsequently decreased more r...
Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The...
Chimeric Antigen Receptor T cell (CAR-T) therapy has shown remarkable success in the treatment of he...
Abstract Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged ...
© 2016 Dr Alexander DavenportDespite the success of autologous chimeric antigen receptor (CAR) T cel...
The chimeric antigen receptor (CAR) directs T cells to target and kill specific cancer cells. Despit...
Adoptive therapy with chimeric antigen receptor (CAR) T cells shows great promise clinically. Howeve...
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeuti...
Abstract Effector T cells equipped with engineered antigen receptors specific for cancer targets hav...
T cell-based immunotherapy has demonstrated great therapeutic potential in recent decades, on the on...
Chimeric antigen receptors (CARs) can mediate redirected lysis of tumour cells in a major histocompa...
International audienceAdoptive transfer of T cells genetically engineered to express chimeric antige...
Chimeric antigen receptor (CAR) T cell immunotherapy is a revolutionary pillar in cancer treatment. ...
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T cells to refr...
Chimeric antigen receptor (CAR)-T cell therapy is rapidly advancing as cancer treatment, however, de...
T cell engineering strategies have emerged as successful immunotherapeutic approaches for the treatm...
Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The...
Chimeric Antigen Receptor T cell (CAR-T) therapy has shown remarkable success in the treatment of he...
Abstract Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged ...
© 2016 Dr Alexander DavenportDespite the success of autologous chimeric antigen receptor (CAR) T cel...
The chimeric antigen receptor (CAR) directs T cells to target and kill specific cancer cells. Despit...
Adoptive therapy with chimeric antigen receptor (CAR) T cells shows great promise clinically. Howeve...
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeuti...
Abstract Effector T cells equipped with engineered antigen receptors specific for cancer targets hav...
T cell-based immunotherapy has demonstrated great therapeutic potential in recent decades, on the on...
Chimeric antigen receptors (CARs) can mediate redirected lysis of tumour cells in a major histocompa...
International audienceAdoptive transfer of T cells genetically engineered to express chimeric antige...
Chimeric antigen receptor (CAR) T cell immunotherapy is a revolutionary pillar in cancer treatment. ...
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T cells to refr...
Chimeric antigen receptor (CAR)-T cell therapy is rapidly advancing as cancer treatment, however, de...
T cell engineering strategies have emerged as successful immunotherapeutic approaches for the treatm...
Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The...
Chimeric Antigen Receptor T cell (CAR-T) therapy has shown remarkable success in the treatment of he...
Abstract Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged ...